Deoxycytidine Kinase Inhibitors Modulating dNTP Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting deoxycytidine kinase (dCK) are limited in effectively inhibiting the enzyme, which is crucial for activating nucleoside analog pro-drugs used in cancer treatment and immune disorders, and for generating dNTPs essential for DNA synthesis.
Innovation Solution
Development of specific compounds with the formula I, which include various substituents allowing for effective binding to dCK, thereby inhibiting its activity, and their use in pharmaceutical compositions for treating cancer and other diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies targeting deoxycytidine kinase are used, then treatment is provided, but the inhibition of dCK is insufficient
Solution Approach 1:
The patent employs parameter changes by modifying chemical structures of dCK inhibitors to optimize binding affinity and enzymatic inhibition. Specific substitutions at different positions of the core structure (e.g., R1, R2, R3, R4, R5, R6 positions) are systematically varied to enhance inhibition efficacy while maintaining selectivity, directly addressing the insufficient inhibition of current therapies
Solution Approach 2:
The patent utilizes composite molecular structures combining multiple functional groups (pyrimidine ring, heterocyclic substituents, aromatic groups) to create potent dCK inhibitors. These composite structures with formula (I) integrate different chemical moieties that work synergistically to achieve reliable enzyme inhibition, overcoming the limitations of simpler current therapies
2Object-affected harmful factors
If dCK activity is inhibited, then nucleoside analog activation is reduced, but toxicity is decreased
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific functional groups at different positions to achieve selective inhibition. The molecular structure (formula I) contains strategically placed substituents (R1-R6) that provide local interactions with the dCK active site, enabling selective binding that reduces off-target toxicity while maintaining sufficient pro-drug activation at the tumor site
Solution Approach 2:
The patent uses dCK inhibitors as intermediaries to modulate the activation of nucleoside analogs. By selectively inhibiting dCK in tumor cells while sparing normal cells, these compounds act as mediators that reduce systemic toxicity of nucleoside analogs while maintaining therapeutic efficacy through localized modulation of pro-drug activation
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3C
AI summary
Provided herein are compounds that bind to dCK and methods for treating cancer.